Clinical Trial

A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke

Study acronym: BCAIS-I
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
BCAIS-I is a single-center, randomized, double-blind, dose-response controlled clinical Trial, to preliminarily explore the efficacy of two different maintenance doses of bevifibatide citrate injection in improving 90-day neurological outcomes and the incidence of symptomatic intracranial hemorrhage in patients with acute ischemic stroke without large or medium-sized vessel occlusion, aiming to identify a dosing regimen that maintains therapeutic efficacy while minimizing the rates of symptomatic intracranial hemorrhage and serious adverse events, thereby providing dosing evidence for future large-scale randomized controlled trials.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-27; most recent amendment 2025-07-15.
Status change: Not Yet Recruiting → Recruiting 2025-05-27
Trial Details
NCT Number NCT06712004
Lead Sponsor Zhujiang Hospital
Conditions Ischemic Stroke, Acute, Ischemic Stroke, Cerebral Infarction, Brain Diseases
Enrollment 40 participants
Start Date 2025-02-10
Primary Completion 2025-09-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-17